How does reimbursement status affect the smoking cessation interventions?

Basit Öğe Kaydı
dc.authorid0000-0002-8025-9877en_US
dc.contributor.authorKaradoğan, Dilek
dc.contributor.authorÖnal, Özgür
dc.contributor.authorKanbay, Yalçın
dc.date.accessioned2020-02-07T08:38:56Z
dc.date.available2020-02-07T08:38:56Z
dc.date.issued2018
dc.departmentAÇÜ, Sağlık Bilimleri Fakültesien_US
dc.description28th International Congress of the European-Respiratory-Society (ERS), Paris, FRANCEen_US
dc.description.abstractBackground and aim: In our country in the last decade smoking cessation outpatient clinics (SCC) were extended countrywide. At first only counseling was under coverage of health insurances. Afterwards, in year 2011 and 2015 free varenicline and bupropion preparats were distributed to SCCs periodically. In that study we aimed to compare our free and not-free medication periods’ outcomes.
dc.description.abstractMethods: Patients applied to SCC in a secondary health care unit between June 2014- June 2017 and evaluated available for SC interventions and had the record of phone visits at their third months were included to the study. Patients were grouped and evaluated according to SCMs’ reimbursement status; free medication period (FP), not-free medication period (NFP).
dc.description.abstractResults: Totally 733 patients applied to SCC and 77.7% of them had applied at the FP. Mean age of the patients was 44.0±13.7, 65% of them were male. Demographic characteristics of patients in both groups were similar, while rate of patients who had comorbid diseases were lower in FP (p<0.05). Treatment choices were different, rate of patients that used adviced treatment at least 30 days (treatment adherent) and rate of quitters at third month were higher in FP (p<0.05). Bupropion prescribed group’s rate was similar, however varenicline was mostly prescribed in FP while NRT was mostly prescribed in NFP (p<0.05).
dc.description.abstractConclusion: Our study showed that free medication period increased not only the quit attemps but also the treatment adherence and quit success of the smokers. Therefore coverage of SCMs should be consistently and include all approved forms.
dc.description.sponsorshipEuropean Respiratory Socen_US
dc.identifier.citationKaradogan, D., Önal, Ö., & Kanbay, Y. (2018). How does reimbursement status affect the smoking cessation interventions?.28th International Congress of the European-Respiratory-Society (ERS). European Respiratory Journal.52. Doi:10.1183/13993003.congress-2018.PA122.en_US
dc.identifier.doi10.1183/13993003.congress-2018.PA1228
dc.identifier.urihttps://hdl.handle.net/11494/1954
dc.identifier.volume52en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.institutionauthorKanbay, Yalçın
dc.language.isoenen_US
dc.publisherEuropean Respiratory Soc Journals Ltden_US
dc.relation.ispartofEuropean Respiratory Journal / 28th International Congress of the European-Respiratory-Society (ERS)
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords Available]en_US
dc.titleHow does reimbursement status affect the smoking cessation interventions?en_US
dc.typeConference Object

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Hemşirelik Bölümü Yayın Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu